Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
Semaglutide injection and CV impact was evaluated using the SUSTAIN-6 trial (designed as a non-inferiority trials), which primarily showed a reduction in the rate of non-fatal stroke events (RR 0.61
Never mix insulin and GLP-1 agonists in the same syringe unless specifically using a combination product designed for this purpose
The American Journal of Clinical Nutrition , 115 (4), 11891193.
The most frequently reported side effects of GLP-1 medications are gastrointestinal in nature
The study can inform policy changes that expand insurance coverage for GLP-1 drugs across a wider range of insurance plans, employment industries, income levels, sex, and other factors